Outcomes Research in Review

Nocturnal Dexmedetomidine for Prevention of Delirium in the ICU


 

References

Applications for Clinical Practice

ICU delirium is an important complication of critical illness and is potentially preventable. Benzodiazepines are associated with an increased risk of delirium, while there has been increasing interest in dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, because of its potential for delirium prevention. Evidence to date does not strongly support routine use of pharmacologic prevention of delirium; however, dexmedetomidine may be an option for sedation, as opposed to benzodiazepines or propofol, in selected patients and may potentially prevent delirium.

—Minkyung Kwon, MD, Neal Patel, MD, and Vichaya Arunthari, MD, Pulmonary and Critical Care Medicine, Mayo Clinic Florida, Jacksonville, FL

Pages

Recommended Reading

CMS finalizes CAR T-cell therapy inpatient payments
Journal of Clinical Outcomes Management
When is the right time to stop treatment?
Journal of Clinical Outcomes Management
Mailing out fecal tests may improve CRC screening rates
Journal of Clinical Outcomes Management
More biosimilars reach the market in efforts to improve access and cut costs
Journal of Clinical Outcomes Management
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
Journal of Clinical Outcomes Management
Hormonal contraceptive use linked to leukemia risk in offspring
Journal of Clinical Outcomes Management
STORM trial shows response in penta-refractory myeloma
Journal of Clinical Outcomes Management
ASCO addresses financial barriers to cancer clinical trials
Journal of Clinical Outcomes Management
Researchers propose new acute leukemia subtypes
Journal of Clinical Outcomes Management
Adjuvant Pembrolizumab Improves Progression-Free Survival in Stage III Melanoma
Journal of Clinical Outcomes Management